Storia in 2 fonti

Adding Immunotherapy-Based Combo Boosts PFS in Unresectable Liver Cancer

But is the higher incidence of grade 3/4 adverse events 'a worthwhile price to pay?' expert asks

Raccontata da

healio.com

medpagetoday.com

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

medpagetoday.comStai leggendo2 mesi fa

Adding Immunotherapy-Based Combo Boosts PFS in Unresectable Liver Cancer

But is the higher incidence of grade 3/4 adverse events 'a worthwhile price to pay?' expert asks

originale

healio.com2 mesi fa

Immunotherapy combination may improve outcomes in unresectable liver cancer

CHICAGO — Adding an immunotherapy-based regimen to standard treatment may improve outcomes for some patients with liver cancer who are not candidates for surgery, according to results of the randomized phase 3 EMERALD-3…

Leggi questa versione → originale

Timeline cronologica

lunedì 1 giugno 2026·healio.com
Immunotherapy combination may improve outcomes in unresectable liver cancer
CHICAGO — Adding an immunotherapy-based regimen to standard treatment may improve outcomes for some patients with liver cancer who are not candidates for surgery, according to…
lunedì 1 giugno 2026·medpagetoday.com
Targeted Combo Boosts PFS in BRAF-Mutant Metastatic Colorectal Cancer
Adding encorafenib and cetuximab to chemotherapy backbone also prolonged overall survival

Adding Immunotherapy-Based Combo Boosts PFS in Unresectable Liver Cancer

Immunotherapy combination may improve outcomes in unresectable liver cancer

Timeline cronologica

Immunotherapy combination may improve outcomes in unresectable liver cancer

Targeted Combo Boosts PFS in BRAF-Mutant Metastatic Colorectal Cancer

More Data Support Trodelvy-Keytruda Combo in Triple-Negative Breast Cancer

Adding Immunotherapy-Based Combo Boosts PFS in Unresectable Liver Cancer